Bristol-Myers Squibb Co Stock Price, News & Analysis

Bristol Myers Squibb (NYSE: BMY) has declared a quarterly dividend of $0.57 per share on its common stock, payable on May 1, 2023, to shareholders of record by April 10, 2023. Additionally, a dividend of $0.50 per share on its $2.00 convertible preferred stock is set for June 1, 2023, payable to stockholders by May 2, 2023. This reflects the company's commitment to returning value to its shareholders while pursuing its mission to develop innovative medicines for serious diseases.

Viz.ai has entered into a multi-year partnership with Bristol Myers Squibb (BMY) to implement an AI algorithm designed to detect and triage patients for hypertrophic cardiomyopathy (HCM). The AI algorithm, which is under FDA review following a de novo classification request, aims to streamline the identification process for patients who may be at risk. HCM affects millions globally, and timely diagnosis can significantly improve outcomes. The collaboration will enhance capabilities within the Viz.ai Cardio Suite, which is currently utilized by around 1,300 U.S. hospitals.

Bristol Myers Squibb (NYSE: BMY) has received full Marketing Authorization from the European Commission for Reblozyl (luspatercept), enabling its use in treating adult patients with non-transfusion-dependent beta thalassemia-associated anemia. This marks Reblozyl's third approval in Europe, complementing existing uses for transfusion-dependent beta thalassemia and myelodysplastic syndromes. The approval is based on the Phase 2 BEYOND study, where 77.1% of patients on Reblozyl achieved significant hemoglobin improvements. The drug is developed in collaboration with Merck following its acquisition of Acceleron Pharma in November 2021.

Bristol Myers Squibb (BMY) has launched the Phase 3 Librexia program, which includes three concurrent trials—Librexia STROKE, Librexia ACS, and Librexia AF—targeting nearly 50,000 patients. This program assesses milvexian, an investigational oral factor XIa inhibitor, for improving outcomes in thrombotic conditions. Enrollment in the Librexia STROKE trial has commenced, aiming to demonstrate superiority in stroke prevention alongside standard antiplatelet therapy. Strong Phase 2 data supports this initiative, showcasing milvexian's potential to enhance the benefit-risk profile in treating acute coronary syndromes and atrial fibrillation.

Bristol Myers Squibb (NYSE: BMY) will participate in a fireside chat at Cowen's 43rd Annual Health Care Conference on March 7, 2023, at 9:50 a.m. ET. Samit Hirawat, M.D., Chief Medical Officer, will address questions about the company's developments.

Investors and the public can access a live webcast of the session at investor.bms.com, with an archived version available later that day.

As a global biopharmaceutical company, Bristol Myers Squibb aims to deliver innovative medicines to help patients overcome serious diseases.

Bristol Myers Squibb announced that the FDA accepted their sBLA and the EMA validated their MAA for Opdivo (nivolumab) as an adjuvant treatment for completely resected stage IIB or IIC melanoma. This follows positive outcomes from the Phase 3 CheckMate -76K trial, which showed a significant benefit in recurrence-free survival (RFS). The FDA set a target action date of October 13, 2023. The CheckMate -76K trial indicated that about 30% of stage IIB and 50% of stage IIC patients experience recurrence within five years post-surgery. Opdivo has shown efficacy across multiple cancers, reinforcing Bristol Myers Squibb's commitment to enhancing cancer treatment.

Bristol Myers Squibb (NYSE: BMY) announced new findings from its CAMZYOS (mavacamten) program at the American College of Cardiology Annual Scientific Session & Expo held March 4-6, 2023. The data strengthens the therapeutic value of CAMZYOS for patients with obstructive hypertrophic cardiomyopathy (HCM). Key presentations included 156-week results from the PIONEER-OLE study, and analyses from the EXPLORER-HCM trial, indicating improved cardiac function across various subgroups. The research reinforces the commitment of Bristol Myers Squibb to developing impactful cardiovascular treatments for patients.

Bristol Myers Squibb and Pfizer have launched the No Time to Wait campaign featuring basketball legend Kareem Abdul-Jabbar. The initiative aims to raise awareness of atrial fibrillation (AFib), a condition affecting an estimated 9.5 million people in the U.S. in 2023, which can lead to significantly increased risk of stroke.

Abdul-Jabbar will share his personal AFib diagnosis story to encourage individuals to consult healthcare professionals regarding their symptoms, which include irregular heartbeat and fatigue. The campaign highlights the importance of early intervention to prevent serious health consequences.

Bristol Myers Squibb (NYSE: BMY) announced promising three-year follow-up results from the Phase 3 CheckMate -274 trial of Opdivo (nivolumab) for high-risk muscle-invasive urothelial carcinoma. Results showed a median disease-free survival of 22.0 months for patients on Opdivo, more than double the 10.9 months for placebo, indicating a 29% risk reduction. In patients with PD-L1 expression ≥1%, median disease-free survival rose to 52.6 months vs. 8.4 months for placebo (HR 0.52). The study demonstrated significant improvements in non-urothelial tract recurrence-free survival and distant metastasis-free survival, highlighting Opdivo's potential in changing urothelial cancer treatment.